Frickenhausen, January 13, 2021 – In its press release published on December 31, 2020, the immunotherapy company BioNTech, based in Mainz, Germany, thanks the laboratory products manufacturer Greiner Bio-One as one of its business partners for its support in the development of the first effective Covid-19 vaccine, which BioNTech recently launched and intends to make available worldwide as soon as possible.
As a systemically relevant company, Greiner Bio-One in Frickenhausen, Germany, manufac-tures laboratory products that play an important role in Sars-CoV-2 diagnostics as well as in vaccine research and production. Like many other pharmaceutical companies, BioNTech relies on Greiner Bio-One products for the development of a Covid-19 vaccine and uses, for example, its 15- and 50-ml tubes, serological pipettes, cryogenic tubes and microplates.
Heinz Schmid and Jakob Breuer, Managing Directors of Greiner Bio-One GmbH, pass on their thanks to their employees: "This once again underlines how important our products are in re-searching and combating the corona virus. We can be justifiably proud of the contribution we are making with our products to overcoming the crisis."
